Discovery of AZD3147: A potent, selective dual inhibitor of mTORC1 and mTORC2

Journal of Medicinal Chemistry

Volumn 58, Issue 5, 2015, Pages 2326-2349

  Pike, Kurt G ^a   Morris, Jeff ^a   Ruston, Linette ^a   Pass, Sarah L ^a   Greenwood, Ryan ^a   Williams, Emma J ^a   Demeritt, Julie ^a   Culshaw, Janet D ^a   Gill, Kristy ^a   Pass, Martin ^a   Finlay, M Raymond V ^a   Good, Catherine J ^a   Roberts, Craig A ^a   Currie, Gordon S ^a   Blades, Kevin ^a   Eden, Jonathan M ^a   Pearson, Stuart E ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM IODIDE; 1-(4-(4-(1-CYCLOPROPYLSULFONYLCYCLOPROPYL)-6-(3-METHYLMORPHOLIN-4-YL)PYRIMIDIN-2-YL)PHENYL)-3-(2-HYDROXYETHYL)THIOUREA; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; THIOUREA; TOR COMPLEX 2;

AQUEOUS SOLUTION; ARTICLE; BINDING SITE; CROSS COUPLING REACTION; CRYSTAL STRUCTURE; HIGH THROUGHPUT SCREENING; HYDROGEN BOND; LIPOPHILICITY; MODEL; MOLECULAR INTERACTION; PROFESSIONAL KNOWLEDGE; PROTEIN STRUCTURE; SYNTHESIS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; LIVER CELL; STRUCTURE ACTIVITY RELATION;

CELLS, CULTURED; DRUG DISCOVERY; HEPATOCYTES; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MULTIPROTEIN COMPLEXES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; THIOUREA; TOR SERINE-THREONINE KINASES;

EID: 84924666080     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501778s     Document Type: Article

References (47)

1. Huang, S.; Houghton, P. J. Targeting mTOR signaling for cancer therapy Curr. Opin. Pharmacol. 2003, 3, 371-377
2. Yap, T. A.; Garrett, M. D.; Walton, M. I.; Raynaud, F.; de Bono, J. S.; Workman, P. Targeting the PI3K-AKT-mTOR pathway:progress, pitfalls, and promises Curr. Opin. Pharmacol. 2008, 8, 393-412
3. Brown, E. J.; Albers, M. W.; Shin, T. B.; Ichikawa, K.; Keith, C. T.; Lane, W. S.; Schreiber, S. L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex Nature 1994, 369, 756-758
4. Sabatini, D. M.; Erdjument-Bromage, H.; Lui, M.; Tempst, P.; Snyder, S. H. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs Cell 1994, 78, 35-43
5. Abraham, R. T. Phosphatidylinositol 3-kinase related kinases Curr. Opin. Immunol. 1996, 8, 412-418
6. Fingar, D. C.; Salama, S.; Tsou, C.; Harlow, E.; Blenis, J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E Genes Dev. 2002, 16, 1472-1487
7. Fingar, D. C.; Richardson, C. J.; Tee, A. R.; Cheatham, L.; Tsou, C.; Blenis, J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E Mol. Cell. Biol. 2004, 24, 200-216
8. Brunn, G. J.; Williams, J.; Sabers, C.; Wiederrecht, G.; Lawrence, J. C., Jr.; Abraham, R. T. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002 EMBO J. 1996, 15, 5256-5267
9. Sarbassov, D. D.; Ali, S. M.; Sabatini, D. M. Growing roles for the mTOR pathway Curr. Opin. Cell Biol. 2005, 17, 596-603
10. Edinger, A. L.; Linardic, C. M.; Chiang, G. G.; Thompson, C. B.; Abraham, R. T. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells Cancer Res. 2003, 63, 8451-8460
11. Sun, S. Y.; Rosenberg, L. M.; Wang, X.; Fu, H.; Khuri, F. R.Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition Cancer Res. 2005, 65, 7052-7058
12. Cloughesy, T. F.; Yoshimoto, K.; Nghiemphu, P.; Brown, K.; Dang, J.; Zhu, S.; Hsueh, T.; Chen, Y.; Wang, W.; Youngkin, D.; Liau, L.; Martin, N.; Becker, D.; Bergsneider, M.; Lai, A.; Green, R.; Oglesby, T.; Koleto, M.; Trent, J.; Horvath, S.; Mischel, P. S.; Mellinghoff, I. K.; Sawyers, C. L. Antitumor activity of rapamycin in a phase I trial for patient with recurrent PTEN-deficient glioblastoma PLoS Med. 2008, 5 (1) e8
13. Garcia-Echeverria, C. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment Bioorg. Med. Chem. Lett. 2010, 20, 4308-4312
14. Faivre, S.; Kroemer, G.; Raymond, E. Current development of mTOR inhibitors as anticancer agents Nat. Rev. Drug Discovery 2006, 5, 671-688
15. Finlay, M. R. V.; Griffin, R. J. Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family Bioorg. Med. Chem. Lett. 2012, 22, 5352-5359
16. Cano, C.; Saravanan, K.; Bailey, C.; Bardos, J.; Curtin, N. J.; Frigerio, M.; Golding, B. T.; Hardcastle, I. R.; Hummersone, M. G.; Menear, K. A.; Newell, D. R.; Richardson, C. J.; Shea, K.; Smith, G. C. M.; Thommes, P.; Ting, A.; Griffin, R. J. 1-Substituted (dibenzo[ b, d ]thiophen-4-yl)-2-morpholino-4 H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity J. Med. Chem. 2013, 56, 6386-6401
17. Walker, E. H.; Pacold, M. E.; Perisic, O.; Stephens, L.; Hawkins, P. T.; Wymann, M. P.; Williams, R. L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine Mol. Cell 2000, 6, 909-919
18. Yang, H.; Rudge, D. G.; Koos, J. D.; Vaidialingam, B.; Yang, H. J.; Pavletich, N. P. mTOR kinase structure, mechanism and regulation Nature 2013, 497, 217-223
19. Finlay, M. R. V.; Buttar, D.; Critchlow, S. E.; Dishington, A. P.; Fillery, S. M.; Fisher, E.; Glossop, S. C.; Graham, M. A.; Johnson, T.; Lamont, G. M.; Mutton, S.; Perkins, P.; Pike, K. G.; Slater, A. M. Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor Bioorg. Med. Chem. Lett. 2012, 22, 4163-4168
20. Walker, E. H.; Pacold, M. E.; Perisic, O.; Ried, C.; Stephens, L.; Williams, R. L. Structural insights into phosphoinositide 3-kinase catalysis and signalling Nature 1999, 402, 313-320
21. Figure 2b was generated using PyMOL: DeLano, W. L. The PyMOL Molecular Graphics System; DeLano Scientific: San Carlos, CA, U.S., 2002; http://www.pymol.org.
22. Assessments of aqueous solubility were made after an incubation of 24 h in pH 7.4 phosphate buffer. After centrifugation, analysis of the supernatant liquid was performed by LC-UV to quantify the amount of compound in solution. Further details are contained in ref 21b.
23. Buttar, D.; Colclough, N.; Gerhardt, S.; MacFaul, P. A.; Phillips, S. D.; Plowright, A.; Whittamore, P.; Tam, K.; Maskos, K.; Steinbacher, S.; Steuber, H. A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions Bioorg. Med. Chem. 2010, 18, 7486-7496
24. Finlay, M. R. V; Morris, J.; Pike, K. G. Morpholinopyrimdine derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use for treating proliferative disorders. PCT Int. Appl. WO2008023159, 2008.
25. Pike, K. G. Morpholinopyrimidine derivatives that are useful in the treatment of diseases mediated by mTOR and/or PI3K enzyme and their preparation. PCT Int. Appl. WO2009007750, 2009.
26. Blades, K.; Demeritt, J.; Fillery, S.; Foote, K. M.; Greenwood, R.; Gregson, C.; Hassall, L. A.; McGuire, T. M.; Pike, K. G.; Williams, E. Expedient synthesis of biologically important sulfonylmethyl pyrimidines Tetrahedron Lett. 2014, 55 (29) 3851-3855
27. Pike, K. G. Pyrimidine derivatives that are useful in the treatment of diseases mediated by mTOR and/or PI3K enzyme and their preparation. PCT Int. Appl. WO2009007748, 2009.
28. Pike, K. G.; Malagu, K.; Hummersone, M. G.; Menear, K. A.; Duggan, H. M. E.; Gomez, S.; Martin, N. M. B.; Ruston, L.; Pass, S. L.; Pass, M. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014 Bioorg. Med. Chem. Lett. 2013, 23, 1212-1216
29. Chresta, C. M.; Davies, B. R.; Hickson, I.; Harding, T.; Cosulich, S.; Critchlow, S. E.; Vincent, J. P.; Ellston, R.; Jones, D.; Sini, P.; James, D.; Howard, Z.; Dudley, P.; Hughes, G.; Smith, L.; Maguire, S.; Hummersone, M.; Malagu, K.; Menear, K.; Jenkins, R.; Jacobsen, M.; Smith, G. C. M.; Guichard, S.; Pass, M. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity Cancer Res. 2010, 70, 288-298
30. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug. Discovery Today 2004, 9, 430-431
31. Albert, J. S.; Blomger, N.; Breeze, A. L.; Brown, A. J. H.; Burrows, J. N.; Edwards, P. D.; Folmer, R. H. A.; Geschwinder, S.; Griffen, E. J.; Kenny, P. W.; Nowak, T.; Olssom, L.-L.; Sanganee, H.; Shapiro, A. B. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes Curr. Top. Med. Chem. 2007, 7, 1600-1629
32. Edwards, M. P.; Price, D. A. Role of physicochemical properties and ligand lipophilicity efficiency in addressing drug safety risks Annu. Rep. Med. Chem. 2010, 45, 381-391
33. Tarcsay, A.; Nyiri, K.; Keseru, G. M. Impact of lipophilic efficency on compound quality J. Med. Chem. 2012, 55, 1252-1260
34. Chiou, W. L.; Robbiel, G.; Chung, S. M.; Wul, T.-C.; Mal, C. Pharm. Res. 1998, 15, 1474
35. Pike, K. G.; Allen, J. V.; Caulkett, P. W. R.; Clarke, D. S.; Donald, C. S.; Fenwick, M. L.; Johnson, K. M.; Johnstone, C.; McKerrecher, D.; Rayner, J. W.; Walker, R. P.; Wilson, I. Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life Bioorg. Med. Chem. Lett. 2011, 21, 3467-3470
36. Murray, C. W.; Erlanson, D. A.; Hopkins, A. L.; Keseru, G. M.; Leeson, P. D.; Rees, D. C.; Reynolds, C. H.; Richmond, N. J. Validity of ligand efficiency metrics Med. Chem. Lett. 2014, 5, 616-618
37. Zask, A.; Kaplan, J.; Verheijen, J. C.; Richard, D. J.; Curran, K.; Brooijmans, N.; Bennett, E. M.; Toral-Barza, L.; Hollander, I.; Ayral-Kaloustian, S.; Yu, K. Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors J. Med. Chem. 2009, 52, 7942-7945
38. Foote, K. M.; Blades, K.; Cronin, A.; Filery, S.; Guichard, S. S.; Hassall, L.; Hickson, I.; Jacq, X.; Jewsbury, P. J.; McGuire, T. M.; Nissink, J. W. M.; Odedra, R.; Page, K.; Perkins, P.; Suleman, A.; Tam, K.; Thommes, P.; Broadhurst, R.; Wood, C. Discovery of 4-{4-[(3 R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1 H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity J. Med. Chem. 2013, 56, 2125-2138
39. Ganellin, R. 1980 Award in medicinal chemistry. Medicinal chemistry and dynamic structure-activity analysis in the discovery of drugs acting at histamine H2 receptors J. Med. Chem. 1981, 24, 913-920
40. Free, S. M., Jr.; Wilson, J. W. A mathematical contribution to structure-activity studies J. Med. Chem. 1964, 7, 395-399
41. Freeman-Cook, K. D.; Amor, P.; Bader, S.; Buzon, L. M.; Coffey, S. B.; Corbett, J. W.; Dirico, K. J.; Dorn, S. D.; Elliott, R. L.; Esler, W.; Guzman-Perez, A.; Henegar, K. E.; Houser, J. A.; Jones, C. S.; Limberakis, C.; Loomis, K.; McPherson, K.; Murdande, S.; Nelson, K. L.; Phillion, D.; Pierce, B. S.; Song, W.; Sugarman, E.; Tapley, S.; Tu, M.; Zhao, Z. Maximising lipophilic efficiency: the use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylase J. Med. Chem. 2012, 55, 935-942
42. Goldberg, F. W.; Leach, A. G.; Scott, J. S.; Snelson, W. L.; Groombridge, S. D.; Donald, C. S.; Bennett, S. N. L.; Bodin, C.; Morentin Gutierrez, P.; Gyte, A. C. Free-Wilson and structural approaches to co-optimizing human and rodent isoform potency for 11β-hydroxysteriod dehydrogenase type 1 (11β-HSD1) inhibitors J. Med. Chem. 2012, 55, 10652-10661
43. Waring, M. J.; Johnstone, C.; McKerrecher, D.; Pike, K. G.; Robb, G. Matrix-based multiparameter optimisation of glucokinase activators: the discovery of AZD1092 Med. Chem. Commun. 2011, 2, 775-779
44. Monolayers of MDCKII (Madin-Darby canine kidney cells) cells transfected with the human MDR1 (multidrug resistance 1) transporter protein were cultured in Transwells and used to study the permeability and efflux potential of compounds at a concentration of 10 μM.
45. Keogh, J. P.; Kunta, J. R. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein Eur. J. Pharm. Sci. 2006, 27, 543-554
46. Redfern, W. S.; Carlsson, L.; Davis, A. S.; Lynch, W. G.; MacKenzie, I.; Palethorpe, S.; Siegl, P. K. S.; Strang, I.; Sullivan, A. T.; Wallis, R.; Camm, A. J.; Hammond, T. G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development Cardiovasc. Res. 2003, I, 32-45
47. The plasma protein binding of compounds was measured using equilibrium dialysis technique and is quoted as the fraction unbound (f u). A more detailed description of the equilibrium dialysis assay conditions are described in Chiou, W. L.; Robbiel, G.; Chung, S. M.; Wul, T.-C.; Mal, C. Correlation of plasma clearance of 54 extensively metabolized drugs between humans and rats: mean allometric coefficient of 0.66 Pharm. Res. 1998, 15, 1474-1479